Concepedia

Roger J. Waltzman

RJ

15

Publications

2.9K

Citations

13

H-Index

1998

Active since

Affiliations

Novartis (Switzerland)(Current)

Memorial Sloan Kettering Cancer Center

Novartis (United States)

Guy's and St Thomas' NHS Foundation Trust

University of Chicago

Roger J. Waltzman is an author at Novartis (Switzerland) specializing in medicine, oncology, and cancer research.

Top concepts

Publications per year

1998–2018

15

Publications

15

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco et al. · Cell · 2018 · 472 citations · Full text

, , +5

Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy

Ann Wexler, Anthony M. Berson, Stephen E. Goldstone et al. · Diseases of the Colon & Rectum · 2007 · 149 citations

Phase II Trial of Paclitaxel in Patients with Soft-Tissue Sarcoma

Ephraim S. Casper, Roger J. Waltzman, Gary K. Schwartz et al. · Cancer Investigation · 1998 · 116 citations

Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy

Roger J. Waltzman, C. Croot, Glen R. Justice et al. · The Oncologist · 2005 · 77 citations · Full text

Rows per page

1–5 of 15